NCT02151747

Testing BRCA 1/2 Mutation Using Next Generation Sequencing

Pilot Study of Validation of Testing BRCA 1/2 Mutation Using Next Generation Sequencing

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 12 (actual)
• Sponsor: Severance Hospital · Academic / Other
• Sex: All
• Age: 19 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Testing BRCA 1/2 mutation is important for patients with breast cancer, and Sanger sequencing is a standard method to identify BRCA 1/2 mutation. Next generation sequencing (NGS) is a high-throughput parallel sequencing that can provide genetic information with high accuracy. NGS is a faster and cost-effective method to detect gene mutations compared to Sanger sequencing. In this study, we evaluated the clinical role of NGS testing for BRCA 1/2 compared to Sanger sequencing.

Conditions

• Breast Neoplasms
• Breast Cancer

Timeline

• Start date: 2014-02-01
• Primary completion: 2015-02-01
• Completion: 2015-02-01
• First posted: 2014-05-30
• Last updated: 2019-10-07

Locations

1 site across 1 country: South Korea